Biocon Publishes Two Phase III Studies Supporting Yesafili FDA Interchangeable Designation

Peer-reviewed Phase III data now anchoring Biocon's U.S. launch strategy for Yesafili™ (aflibercept-jbvf) raises the evidentiary bar for biosimilar manufacturers pursuing interchangeability designation, a regulatory pathway that demands demonstration of equivalent switching outcomes, not just analytical similarity. Two publications from the INSIGHT program, released across separate journals, collectively address the two most scrutinised dimensions of any interchangeability package: switch-study safety and subgroup consistency.

The first manuscript, published in the British Journal of Ophthalmology on June 29, 2026, reports 20-week open-label extension data from the INSIGHT pivotal trial in diabetic macular edema (DME). Participants who switched from reference aflibercept to MYL-1701P showed comparable safety, efficacy, and immunogenicity profiles to those who continued on the biosimilar throughout. Endpoints included best corrected visual acuity, central subfield thickness, and ETDRS letter gains, the standard functional and anatomic measures regulators expect in retinal biosimilar programs.

The second manuscript, published in Expert Opinion on Biological Therapy on May 18, 2026, presents exploratory subgroup analyses from the same Phase III randomised trial. Subgroups were stratified by baseline visual acuity, central subfield thickness, age, sex, race, ethnicity, geographic region, glycated haemoglobin, anti-drug antibody status, and prior anti-VEGF therapy, a breadth of stratification that supports clinical equivalence claims across heterogeneous DME populations. For QA and regulatory leads, the anti-drug antibody subgroup data carries particular weight, given immunogenicity comparability requirements under FDA biosimilar guidance and ICH Q6B analytical standards.

Biocon received FDA approval and interchangeable designation for Yesafili's vial format in May 2024 under 21 CFR Part 601 biosimilar provisions. The interchangeable designation is consequential for plant heads scaling U.S.-market production: it permits pharmacist-level substitution without prescriber intervention, which materially affects volume forecasting and batch scheduling relative to a standard biosimilar launch. Manufacturing teams preparing for commercial supply will need to ensure that process validation packages and continued process verification protocols are aligned to the reference product comparability data now in the public domain.

The publication of switch-study and subgroup data in peer-reviewed journals also establishes a documented evidence base that supports post-approval commitments and any future label negotiations, a checkpoint that regulatory affairs leads should track as Biocon moves toward its stated U.S. launch.

Source: Biocon Limited via press release, July 9, 2026.